复星医药(02196.HK)子公司参建基金 投资生物医药等项目
复星医药(02196.HK)(600196.SH)公布,控股子公司/企业南京复鑫、宁波复瀛拟与包括关联方复星高科技在内的其他4方投资人共同出资设立目标基金,其中南京复鑫、宁波复瀛、复星高科技拟分别以现金出资1,010万元人民币(下同)、3.2亿元、2亿元认缴目标基金中的等值财产份额。
目标基金设立完成後,拟聘任公司控股子公司复健基金管理公司为目标基金的基金管理人。
目标基金主要投资生物医药、医疗器械及诊断、生物材料、精准治疗等领域项目。目标基金计划募集资金15亿元,其中首轮拟募集资金约10.1亿元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.